-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mirati Therapeutics announced positive results from a Phase 2 clinical trial of its KRAS G12C inhibitor adagrasib in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutati.
Adagrasib is a highly specific and potent oral KRAS G12C inhibitor optimized for durable target inhibiti.
As of October 15, 2021, among 112 evaluable patients, the objective response rate was 43% and the disease control rate was 8
The company also published results from a retrospective exploratory analysis of a subset of patients with stable, previously treated central nervous system (CNS) metastases in the Phase 2 clinical tri.
In terms of safety, the safety profile of adagrasib in this study was similar to previous reports, and no new safety signals were identifi.
References:
[1] Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Canc.
(Original abridged)
